Format

Send to

Choose Destination
See comment in PubMed Commons below
Nat Commun. 2016 Feb 19;7:10759. doi: 10.1038/ncomms10759.

Antibody-based PET imaging of amyloid beta in mouse models of Alzheimer's disease.

Author information

1
Department of Public Health and Caring Sciences/Geriatrics, Uppsala University, Rudbeck Laboratory, 75185 Uppsala, Sweden.
2
Department of Medicinal Chemistry, Preclinical PET Platform, Uppsala University, 75123 Uppsala, Sweden.
3
PET Centre, Uppsala University Hospital, 75185 Uppsala, Sweden.

Abstract

Owing to their specificity and high-affinity binding, monoclonal antibodies have potential as positron emission tomography (PET) radioligands and are currently used to image various targets in peripheral organs. However, in the central nervous system, antibody uptake is limited by the blood-brain barrier (BBB). Here we present a PET ligand to be used for diagnosis and evaluation of treatment effects in Alzheimer's disease. The amyloid β (Aβ) antibody mAb158 is radiolabelled and conjugated to a transferrin receptor antibody to enable receptor-mediated transcytosis across the BBB. PET imaging of two different mouse models with Aβ pathology clearly visualize Aβ in the brain. The PET signal increases with age and correlates closely with brain Aβ levels. Thus, we demonstrate that antibody-based PET ligands can be successfully used for brain imaging.

PMID:
26892305
PMCID:
PMC4762893
DOI:
10.1038/ncomms10759
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group Icon for PubMed Central
    Loading ...
    Support Center